3

FORM 3 SUBMISSION

Company: Viridian Therapeutics, Inc.\DE
Filed: February 7, 2023
Period of Report: February 6, 2023
Accession Number: 0000899243-23-004235

View Document ↗ View on SEC.gov ↗